Please assess the completion status of the following clinical trial:

Trial Title: Investigation of Contralateral Arytenoid Sparing IMRT for T1a & T2a Larynx Cancer & Analysis of Post-treatment Laryngeal Function

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
* Inclusion Criteria:~  * Patients with T1a or T2a squamous cell carcinoma of the glottic larynx (tumor limited to one vocal cord with normal cord mobility).~ * Patients must be able to read and write English to comply with the questionnaire portions of the protocol.~ * ECOG performance status of 0 or 1.~* Exclusion Criteria:~  * Patients with verrucous or adenocarcinoma~ * Patients with T1 tumors on both cords (T1b)~ * Patients with T2b-T4 true larynx tumors~ * Patients with primary supraglottic tumors that involve the true larynx~ * Patients with a prior or concurrent malignancy (other than nonmelanoma skin cancer or carcinoma in-situ of the cervix) are ineligible unless the previous cancer was treated 5 years or more prior to the current tumor and the patient has remained continually disease free~ * Patients who have received prior radiation to the head and neck~ * Pregnant or breastfeeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IMRT Radiation (Type: EXPERIMENTAL): All subjects will be treated using IMRT with the standard fractionation for T1a glottic cancer at Fox Chase Cancer Center: 63 Gy in 28 fractions; 6 for T1a and 65.25 Gy in 29 fractions; 33 for T2a. Treatment will be followed by functional assessments performed at months 1,3,6,12,and 24.

Based on this trial design, predict the completion outcome and termination type (if applicable).